E-resources
Peer reviewed
Open access
-
Rosati, Gerardo; Cella, Chiara Alessandra; Cavanna, Luigi; Codecà, Carla; Prisciandaro, Michele; Mosconi, Stefania; Luchena, Giovanna; Silvestris, Nicola; Bernardini, Ilaria; Casaretti, Rossana; Zoratto, Federica; Amoroso, Domenico; Ciarlo, Andrea; Barni, Sandro; Cascinu, Stefano; Davite, Cristina; Di Sanzo, Alessandro; Casolaro, Alessia; Bilancia, Domenico; Labianca, Roberto
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 07/2022, Volume: 25, Issue: 4Journal Article
Background EOX (epirubicin, oxaliplatin, and capecitabine) is one of the standard regimens for metastatic or locally advanced gastric cancer (GC). A new combination based on fractional docetaxel (low-TOX) has been developed in an attempt to increase the efficacy of EOX and reduce the heavy toxicity of classical docetaxel regimens. Methods Overall, 169 previously untreated GC patients were randomized between EOX ( arm A ) and low-TOX ( arm B ). The primary endpoint was progression-free survival (PFS), while secondary ones were overall survival (OS), overall response rate (ORR), disease control rate (DCR), and tolerability. The study was designed to detect a 35% (80% power at a two-sided 5% significance level) PFS increase with low-TOX and an interim analysis for futility was planned after the first 127 events. Results At the cut-off date of interim analysis, median PFS was 6.3 months 95% confidence interval (CI) 5.0–8.1 in arm A vs 6.3 months (95% CI 5.0–7.8) in arm B , without statistical difference. OS was comparable in the two arms: 12.4 in arm A (95% CI 9.1–19.2) vs 11.5 months in arm B (95% CI 8.6–15.0). ORR was 33% and 24%, while DCR was 68% and 67%, respectively. Treatment modification (91% vs 78%, P = 0.017) and number of patients with CTC grade ≥ 3 adverse events (42 vs 35) were higher in arm B. Conclusions A triplet regimen based on the fractional dose of docetaxel achieves no improvement over EOX which remains a potential standard treatment in many patients with inoperable, locally advanced or metastatic GC.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.